PT-141 nasal spray: does it work?

Reviewed 17 sourcesPublished by PepVault

PT-141 nasal spray worked in early trials but absorbed unevenly. The nasal studies by species, the FDA's 2007 blood-pressure concern, and why it became a shot.

A couple in white and light-blue linen walking hand in hand at the water’s edge at sunrise
Last reviewed
Sources
17
Questions
5
Compounds
2

The short answer

Yes, the nose absorbs PT-141 (bremelanotide), but unevenly. In its developer's nasal trials, sprays of more than 7 mg produced erections in men, and 20 mg raised desire in a small study of women. Blood levels varied widely from person to person, the FDA named blood pressure rises its greatest safety concern in 2007, and the drug was rebuilt as an injection. No nasal form is FDA-approved.

Every number checked at its primary source · · 17 sources · How we research

Evidence: Nasal route: phase 1 and 2 trials in men (one large at-home program never published in a journal), one 18-woman crossover study and animal work. The only approved form is the injection, tested in phase 3.

A couple in white and light-blue linen walking hand in hand at the water’s edge at sunrise

Does the nose absorb PT-141?

PT-141 was born as a nasal spray. Palatin Technologies, the company that made it, developed it as a single spray in one nostril13, though its early trials in men also tested injections2. In healthy men the spray reached its peak in the blood at about 30 minutes, blood levels rose with the dose, and the half-life (the time for the level to fall by half) was 1.85 to 2.09 hours1.

The catch is how much gets in. Bioavailability is the share of a dose that reaches the bloodstream. Injected under the skin, the approved form delivers about 100%16. A 20 mg nasal dose gave about the same exposure as 1 to 2 times the 1.75 mg injection7. Our arithmetic from those two numbers: roughly 9 to 18% of a sprayed dose reached the blood, compared with the shot.

MeasureNasal spray (trials only)Injection under the skin (Vyleesi)
Doses testedUp to 20 mg in men and women1471.75 mg, the label's dose16
Peak in the bloodAbout 30 minutes1About 1 hour16
Half-life1.85 to 2.09 hours12.7 hours (1.9 to 4.0)16
Share reaching the bloodAbout 9 to 18% of the dose, by our arithmetic716About 100%16
From one person to the nextWide variation in blood levels814Tighter, more predictable814
FDA statusNever approved; development stopped1417Approved June 201917

So the route works in the narrow sense: the peptide crosses the lining of the nose and does something. The trouble was never whether it gets in, but how much, and how differently from one person to the next.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault records each compound's route, nasal spray or injection, and logs an as-needed compound when you take it, with no missed-dose marks. Nausea or flushing can go on the Side effects page against that day.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the nasal trials find?

Here is every nasal study we could find at a primary source, grouped by species, with the injection studies in men and the animal work beside them for comparison.

WhoRoute and study doseWhat it found
Rats and monkeys10Given to the animals (route not stated in the summary)Erections in male rats and monkeys
Female rats9Given to the animals (route not stated in the summary)More soliciting of males, with no other change in sexual behaviour
Healthy men, and men with mild to moderate erectile dysfunction1Nasal, single dosesErections beat placebo above 7 mg, the first one at about 30 minutes; flushing and nausea most common
19 men with erectile dysfunction3Nasal 7.5 mg plus 25 mg sildenafil, crossoverThe pair produced more erection than sildenafil alone
342 men for whom sildenafil had failed5Nasal 10 mg, at least 16 tries at home33.5% had a good result vs 8.5% on placebo; under an expression of concern since 2023
726 men without and 294 with diabetes (phase 2B)1314Nasal, a range of doses, 3 months at homeOver 30% restored to normal function, in the company's words; never published in a journal
18 premenopausal women with arousal disorder4Nasal 20 mg, single dose, crossoverMore reported moderate or high desire than on placebo; blood flow in the vagina did not change
Postmenopausal women (phase 2, 8 weeks at home)15NasalCompleted in 2007; no results on the registry or in a journal
12 healthy men and 12 healthy women7Nasal 20 mg, with or without alcoholNo interaction with alcohol; no one stopped for side effects
Healthy men, then men who responded poorly to Viagra2Injection, 0.3 to 10 mg (4 or 6 mg in the patients)Erections beat placebo above 1 mg in healthy men and at both doses in the patients

The first two rows are animal studies; rats and monkeys show that the receptors respond, not what a person will feel. A 2008 bremelanotide trial in women by the author of the 342-man study was retracted in full by its journal, so it is left out of the table6.

Read across the rows and the pattern is plain. In men, the spray reliably produced erections in the clinic, measured with RigiScan, a gauge worn on the penis, and the large at-home phase 2B trials found a benefit. In women, the nasal evidence is one 18-woman crossover study, a design where each woman takes both the drug and the placebo on different days, plus a trial whose results were never released415. The doses that worked by nose (7 to 20 mg) are several times the 1.75 mg that works by injection, which fits the low share that gets through1416.

Why did Palatin stop the nasal spray?

Blood pressure. In late August 2007, after reviewing the nasal phase 1 and 2 data for erectile dysfunction, FDA reviewers "raised serious concerns about the acceptable benefit/risk ratio", "questioned the overall efficacy results", and "cited blood pressure increases as its greatest safety concern"11. Palatin and its partner King Pharmaceuticals delayed phase 3, and King ended the partnership within a week1112.

Palatin's own explanation came in its annual reports. Blood pressure rose in some patients on the spray, and that rise was "a significant factor" in ending nasal development. The company tied the blood pressure rises, and the rate of nausea and vomiting, at least partly to "variability in drug uptake with nasal administration": blood levels varied widely between patients14. A later paper by Palatin's researchers and two academic blood pressure specialists said the same in plain terms: the spray could push some people above the level needed while leaving others with too little8.

That is the mechanism. PT-141 switches on melanocortin-4 receptors (MC4R) in the brain, and MC4R activity can raise blood pressure8. Through the nose, some people absorbed far more than others, so the same spray could overshoot in one person and fall short in the next814. Under the skin about 100% of the dose arrives16, and Palatin measured much less variation from one person to the next14.

Did the injection fix the blood pressure problem?

It made the effect small and predictable; it did not remove it. In a company phase 1 study of repeated injections, mean blood pressure did not differ from placebo, and no one stopped under the study's blood pressure rules14. Then a phase 2 trial in 397 premenopausal women wore 24-hour blood pressure monitors at three injected doses8.

MeasureInjected 1.25 mgInjected 1.75 mg
Rise in systolic pressure vs placebo, 0 to 4 hours after the dose2.4 and 3.0 mmHg on the two test days83.1 and 3.2 mmHg on the two test days8
Fall in heart rate vs placeboSimilar in every dose group: means of 4.8 to 6.6 beats a minute over the first 8 hours84.6 to 4.7 beats a minute, 0 to 4 hours8

The peaks usually lasted less than 15 minutes. About 7% of the women were withdrawn over their blood pressure readings, in similar shares on placebo (6%) and on the drug (4 to 9%), and the size of the rise did not track the level in the blood8. The Vyleesi label now gives the approved dose's effect: systolic pressure up by as much as 6 mmHg and diastolic by 3, peaking 2 to 4 hours after the dose, with the heart rate down by up to 5 beats a minute, usually back to baseline within 12 hours16.

The label's own words set the limit: Vyleesi "is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease" and "is not recommended for patients at high risk for cardiovascular disease"16. Whether a person's heart and blood pressure allow it is the prescriber's decision, made before the first dose.

When to get help If you have high blood pressure or heart disease, that is a conversation for the prescriber before any dose; chest pain, a severe headache or a pounding heartbeat after a dose is a reason to get medical help the same day.

Is there an approved PT-141 nasal spray?

No. Drugs@FDA lists one bremelanotide product: Vyleesi, 1.75 mg in 0.3 mL, in a single-dose autoinjector for injection under the skin17. Its label covers premenopausal women with acquired, generalized hypoactive sexual desire disorder and says it is not for men16. What the trials found with that shot, and its nausea and skin-darkening rates, is in our PT-141 (bremelanotide) guide.

A nasal spray sold as PT-141 is a different product from anything the FDA reviewed: nobody has checked how much of its labelled amount reaches the blood, or how evenly. The trial numbers do not carry over either. The nasal studies used 7.5 to 20 mg in a single spray1347, while the approved injection is 1.75 mg16; a milligram in the nose and a milligram under the skin are not the same amount of drug in the body.

Commonly reported: people who have used nasal PT-141 describe effects that vary more from one dose to the next than with injections, a brief sting or runny nose after spraying, and the same flushing and nausea the trials recorded.

PepVault records each compound's route, nasal spray or injection, and logs an as-needed compound when you take it, with no missed-dose marks. Nausea or flushing can go on the Side effects page against that day. Log it in PepVault

Track it in the app

Sources

  1. Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PubMed 14963471
  2. Rosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PubMed 14999221
  3. Diamond LE et al. Co-administration of low doses of intranasal PT-141 and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005. PubMed 15833522
  4. Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006. PubMed 16839319
  5. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 (expression of concern, 2023). PubMed 18206919
  6. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide in female subjects with arousal disorder. J Sex Med. 2008 (retracted). PubMed 18179455
  7. Clayton AH et al. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants. Clin Ther. 2017. PubMed 28189361
  8. White WB et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017. PubMed 27977473
  9. Pfaus JG et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004. PubMed 15226502
  10. Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003. PubMed 12851303
  11. Palatin Technologies and King Pharmaceuticals. Press release: delay of immediate plans for a phase 3 program with bremelanotide for erectile dysfunction. August 30, 2007 (SEC Form 8-K, exhibit 99). sec.gov
  12. Palatin Technologies. Form 8-K: termination of the bremelanotide collaboration with King Pharmaceuticals. September 6, 2007. sec.gov
  13. Palatin Technologies. Annual report (Form 10-K) for the fiscal year ended June 30, 2007. sec.gov
  14. Palatin Technologies. Annual report (Form 10-K) for the fiscal year ended June 30, 2009: clinical trials with intranasal formulations, subcutaneous administration. sec.gov
  15. ClinicalTrials.gov NCT00425256: intranasal bremelanotide in women with female sexual arousal disorder, phase 2, 8 weeks at home. Palatin Technologies. clinicaltrials.gov
  16. Vyleesi (bremelanotide injection) prescribing information. Cosette Pharmaceuticals. Revised October 2026 (DailyMed). dailymed.nlm.nih.gov
  17. Drugs@FDA: NDA 210557, Vyleesi (autoinjector), subcutaneous solution; original approval June 21, 2019. accessdata.fda.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo